Resolian, a portfolio company of Ampersand Capital Partners, announced that it acquired Denali Medpharma.
Denali Medpharma is a Chinese bioanalytical contract research organization (CRO). It is well known as the industry leader in China in the bioanalysis of oligonucleotide drugs and mRNA vaccines, liposomal drug, ultra-sensitive assays for inhalation drugs and biomarker assays.
Resolian (formerly Alliance Pharma Inc. and Drug Development Solutions Ltd.) is a CRO that specializes in advanced bioanalytical research services for small and large molecule drugs. It also specializes in drug metabolism studies to support pharmaceutical and biotechnology companies’ drug discovery and development programs.
This transaction expands Resolian’s CRO capabilities in China. The financial terms of the acquisition were not disclosed.
According to data captured in the LevinPro HC database, this transaction marks the 35th CRO acquisition of the year. This is also Resolian’s first transaction of the year.
